Johnson & Johnson's single-dose COVID-19 vaccine trial reaches full enrollment

[perugu_vada]

Johnson & Johnson announced it reached full enrollment for its late-stage single-dose coronavirus vaccine trial with about 45,000 participants. 

Company officials said interim data, or data released before the trial is over, is expected by the end of January 2021. Though this news lags behind other companies on the COVID-19 vaccine front, like Pfizer and Moderna, officials welcome as many vaccine candidates as possible in order to meet global demand and ultimately conquer the ongoing health crisis.

If data suggests the vaccine is safe and effective, Johnson & Johnson said it expects to file for an emergency approval from the U.S. Food and Drug Administration in February. 

[athili_duvva_combo]

@perugu_vada does this vaccine handle the new strain in UK?